Chemical Information
Antiviral agent ID	DrugRepV_7701
Antiviral agent name	Pegasys
Structural Information
2-D Structure is not available	3-D Structure is not available
Clinical Information
Primary Indication (Clinical trial phases)	Approved, Investigational
Biological Information
Primary Indication (Disease Category)	Infectious Disease
Primary Indication (Disease)	Hepatitis C Virus
Secondary Indication	SARS Coronavirus-2 (SARS-CoV-2) 2
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Duration of drug delivery)	72 hours
Secondary Indication (Drug concentration)	1068 IU/mL
Secondary Indication (Cell based assay)	Plaque reduction assay
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	EC50 [ 50 % ]
Reference	Yuan S, Chan CC, Chik KK, Tsang JO, Liang R, Cao J, Tang K, Cai JP, Ye ZW, Yin F, To KK, Chu H, Jin DY, Hung IF, Yuen KY, Chan JF..Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)..Viruses. 2020 Jun 10;12(6):E628. doi: 10.3390/v12060628. PMID:32532085
Comment	The lipogenesis modulators 25-hydroxycholesterol and AM580 exhibited EC50 at low micromolar levels and selectivity indices of >10.0 against SARS-CoV-2